Metastatic and recurrent anal squamous cell carcinoma: lines of therapy
4 standard-of-care settings across 3 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
Advanced, first line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | First line | Carboplatin and paclitaxel with retifanlimab (POD1UM-303, approved 2025); carboplatin and paclitaxel alone (InterAACT) where the antibody is unavailable or contraindicated. | NCCN Guidelines: Anal Carcinoma | 99 |
Second line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | After platinum chemotherapy | Nivolumab (NCI9673) or pembrolizumab (KEYNOTE-158) if no prior PD-1 antibody; fluorouracil-based or taxane chemotherapy otherwise. | NCCN Guidelines: Anal Carcinoma | 98 | |
| All comers | Isolated pelvic recurrence | Salvage abdominoperineal resection when the tumour is resectable; re-irradiation is rarely possible. | NCCN Guidelines: Anal Carcinoma | 40 |
Special situations
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Oligometastatic disease | Resection or stereotactic radiotherapy of limited liver or lung metastases alongside systemic therapy, on a case basis. | NCCN Guidelines: Anal Carcinoma | 40 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.